Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

BACKGROUND: Enzalutamide (Enz) has shown limited bioavailability via oral administration. Castration-resistant prostate cancer (CRPC) is frequent among patients receiving 18–24 months of androgen deprivation therapy. The nonsteroidal anti-androgen enzalutamide (Enz) used in the treatment of prostate...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Nanobiotechnology
Main Authors: Jiang, Wenjun, Chen, Jiyuan, Gong, Chunai, Wang, Yuanyuan, Gao, Yuan, Yuan, Yongfang
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7079409/
https://ncbi.nlm.nih.gov/pubmed/32188463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12951-020-00607-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares